Drug Details

General Information of the Drug (ID: DR8551)
Name
Decitabine
Synonyms
AzadC; Dacogen; Dezocitidine; NCGC_5ADOC; Dacogen (TN); E-7373; Decitabine (USAN/INN); Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine; 2'-Deoxy-5-azacytidine; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 5-AZAdC; 5-Aza-2′ 5-Azadeoxycytidine; 5-Deoxy-2′ 5-aza-2-deoxycytidine; 5-aza-CdR; 5-aza-dC; 5A2dc
    Click to Show/Hide
Molecular Type
Small molecule
Disease Myelodysplastic syndrome [ICD-11: 2A37] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C8H12N4O4
PubChem CID
451668
Canonical SMILES
C1C(C(OC1N2C=NC(=NC2=O)N)CO)O
InChI
1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
InChIKey
XAUDJQYHKZQPEU-KVQBGUIXSA-N
CAS Number
CAS 2353-33-5
ChEBI ID
CHEBI:50131
TTD Drug ID
D0X5XU
DrugBank ID
DB01262
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Arsenic trioxide      Realgar and orpiment     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model MV4-11 CVCL_0064 Childhood acute monocytic leukemia Homo sapiens
                    Experimental
                    Result(s)		 Effect of decitabine in combination with arsenic trioxide on prolife-ration and apoptosis of human acute myeloid leukemia MV4-11 cells.
          Genistein      Glycine max     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model HL-60 CVCL_0002 Adult acute myeloid leukemia Homo sapiens
MOLT-3 CVCL_0624 Adult T acute lymphoblastic leukemia Homo sapiens
L1210 CVCL_0382 Mouse leukemia Mus musculus
                    In-vivo Model Male CD2F1 mice (24-28 g) were injested with L1210 leukemic cells intravenously into the lateral tail vein.
                    Experimental
                    Result(s)		 The combined treatment produced a synergistic loss of clonogenicity in human myeloid (HL-60) and lymphoid (MOLT-3) leukemic cell lines.
          Paclitaxel      Taxus brevifolia     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [4]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression TGFB1  Molecule Info 
Pathway MAP
                    In-vitro Model ACHN CVCL_1067 Papillary renal cell carcinoma Homo sapiens
Caki-1 CVCL_0234 Clear cell renal cell carcinoma Homo sapiens
Caki-2 CVCL_0235 Renal cell carcinoma Homo sapiens
NC 65 Renal cell carcinoma Homo sapiens
                    In-vivo Model 1*107 ACHN or Caki-1 cells were injected into the backs of each mouse.
                    Experimental
                    Result(s)		 Paclitaxel in combination with 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma through VHL-TGFBI signaling.
          Sulforaphane      Brassica oleracea     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [5]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model B16-F10 CVCL_0159 Mouse melanoma Mus musculus
                    Experimental
                    Result(s)		 combinational treatments with SFN and DAC results in melanoma cell growth inhibition and specific changes in gene expression profiles.
Target and Pathway
Target(s) Human Deoxyribonucleic acid (hDNA)  Molecule Info  [6]
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6805).
Reference 2 [Effect of Decitabine in Combination with Arsenic Trioxide on Prolife-ration and Apoptosis of Human Acute Myeloid Leukemia MV4-11 Cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Oct;24(5):1343-1347.
Reference 3 Synergistic effect of 5-Aza-2'-deoxycytidine and genistein in combination against leukemia. Oncol Res. 2008;17(5):223-30.
Reference 4 VHL-TGFBI signaling is involved in the synergy between 5-aza-2'-deoxycytidine and paclitaxel against human renal cell carcinoma. J BUON. Mar-Apr 2017;22(2):500-507.
Reference 5 Effect of Sulforaphane and 5-Aza-2'-Deoxycytidine on Melanoma Cell Growth. Medicines (Basel). 2019 Jun 27;6(3):71.
Reference 6 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link